Subscribe to RSS



Amgen, Inc. (NASDAQ:AMGN) Announces Lower Profit In 4Q on Higher Spending – AMGN, ARNA, DNDN, ACAD, ALXN

Amgen, Inc. (NASDAQ:AMGN) unveiled on Wednesday a 16% decrease in fourth-quarter profit, as high production costs, marketing, research and other items counterbalance higher sales for a lot of its biologic medicines. The results dropped a small piece of Wall Street anticipations.

The world’s largest biotech firm, based in Thousand Oaks, Calif., reported net income was $788M, or $1.01 a share, for the quarter ended Dec. 31. That was decreased from $934M, or $1.08 a share, a year before.

While the excluding one-time items, net income would have been $1.40 a share. That is 4 cents lower than analysts anticipated, on average, according to research provider FactSet.

Shares of Amgen, Inc. (NASDAQ:AMGN) traded at $83.07 by plunging -0.26% with price volatility of 1.80% for a week and 1.63% for a month plus price volatility’s Average True Range for 14 days was 1.41 and its beta stands at 1.63 times.

Stocks after opening at $83.06 hit high price of $84.49 and on last session stock held volume of 7.67 million shares which was unexpectedly higher than its average volume of 4.75 million shares.

Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 3.90 as current ratio and on the opponent side the debt to equity ratio was 1.33 and long-term debt to equity ratio also remained 1.21. The Company had total cash at hand $25.37 billion and a book value per share as $25.91 in the most recent quarter.

While investors who viewing AMGN against other stocks with the reference of profit margin that are Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) having profit margin -316.94%, Dendreon Corporation (NASDAQ:DNDN) with -71.65% profit margin, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) having -378.08% profit margin and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) having profit margin of 21.32%.

 


Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here

0 comments

Other articlesgo to homepage

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Shares of Zalicus Inc. (Nasdaq:ZLCS) skyrocketed $0.32 (or +31.07%) to $1.35, following the announcement that Epirus Biopharmaceuticals, Inc., which has closed a $36 million Series B financing round, will merge with a wholly-owned subsidiary of Zalicus, to create a global biosimilar enterprise. 13,616,255 shares of Zalicus were traded on Wednesday, increased activity versus its average

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

The trading levels of SmartPros Ltd. (Nasdaq:SPRO) stock exploded on Monday’s market activity, closing at $2.99, up $0.77 (or +34.68%), and 334,315 of its shares exchanged hands during the day, a large increase on activity versus its average volume (3m) of 7,818 On intraday trading, SPRO stock reached a new 52 week high of $3.30

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Shares of JAKKS Pacific, Inc. (Nasdaq:JAKK) soared $0.75 (or +9.96%) to $8.28, and 1,043,882 of its shares exchanged hands on Friday’s trading session. JAKKS Pacific, a leading designer and marketer of toys and consumer products, was upgraded from Market Perform to Outperform and its price target raised from $8.00 to $10.00 by brokerage firm BMO

Crown Equity Holdings Inc Surges on CRWE-PR network Achievement (OTCMKTS:CRWE)

Crown Equity Holdings Inc Surges on CRWE-PR network Achievement (OTCMKTS:CRWE)

With today’s stock market pullback in session, you can take a look at over-the-counter securities (OTC) – Crown Equity Holdings Inc ticker symbol (OTCMKTS:CRWE). Crown Equity Holdings Inc stock price has surged today as high as +13.64% Up 0.0009, currently at +6.06% Up 0.0004, just shy of 300K shares in play in the financial market

BofI Holding Inc (Nasdaq:BOFI) and H&R Block Inc (NYSE:HRB) Could Soar on Win-Win Deal, Titan Machinery Inc (Nasdaq:TITN) Surges on Top Line Results

BofI Holding Inc (Nasdaq:BOFI) and H&R Block Inc (NYSE:HRB) Could Soar on Win-Win Deal, Titan Machinery Inc (Nasdaq:TITN) Surges on Top Line Results

BofI Holding, Inc. (Nasdaq:BOFI) said that its subsidiary BofI Federal Bank has agreed to provide banking products to H&R Block clients. BofI Federal Bank also would buy H&R Block, Inc.‘s (NYSE:HRB) bank unit. The deal is attracting investors’ attention for both companies in after hours trading. Shares of BofI Holding closed at $74.44, down $2.27

read more

Sign Up*

Receive Our Newsletter!

 



 

 

Contacts and information

Social networks

Most popular categories

© 2014 Crown Equity Holdings Inc. All rights reserved.